Capromab Pendetide imaging of prostate cancer

Abstract

Capromab Pendetide imaging enables more accurate disease staging in patients with prostate cancer than is afforded by other imaging modalities such as CT and MRI. In the primary disease setting, Capromab Pendetide imaging should be reserved for patients with negative bone scans who are at high risk for metastatic disease. In the recurrent disease setting, this technique is helpful in identifying those patients most likely to respond to salvage therapy. Capromab Pendetide imaging is a technically demanding procedure that is best performed at sites with experience and expertise.